Security Snapshot

AVANOS MEDICAL, INC. - Common Stock - $0.01 Par Value (AVNS) Institutional Ownership

CUSIP: 05350V106

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

247

Shares (Excl. Options)

44,822,191

Price

$14.01

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock - $0.01 Par Value
Symbol
AVNS on NYSE
Shares outstanding
46,511,628
Price per share
$24.66
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
44,822,191
Total reported value
$627,677,917
% of total 13F portfolios
0%
Share change
-509,369
Value change
-$2,871,053
Number of holders
247
Price from insider filings
$24.66
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • AVNS - AVANOS MEDICAL, INC. - Common Stock - $0.01 Par Value is tracked under CUSIP 05350V106.
  • 247 institutions reported positions in Q1 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 271 to 247 between Q4 2025 and Q1 2026.
  • Reported value moved from $509,776,106 to $627,677,917.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 247 institutions filings for Q1 2026.

Open SEC Evidence

Security key

05350V106

Latest holder period

Q1 2026

13F holders

247

13D/G owners

4

CIK / CUSIP context first

Open Q1 2026 holders AVNS full holder history AVANOS MEDICAL, INC. SEC filings AVANOS MEDICAL, INC. company facts AVANOS MEDICAL, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of AVANOS MEDICAL, INC. - Common Stock - $0.01 Par Value (AVNS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% $84,305,460 6,826,353 BlackRock, Inc. 31 Mar 2025
DIMENSIONAL FUND ADVISORS LP 4.6% -10% $24,230,152 -$2,191,104 2,157,531 -8.3% Dimensional Fund Advisors LP 31 Dec 2025
ARMISTICE CAPITAL, LLC 4.3% -37% $29,060,000 -$17,436,000 2,000,000 -38% Armistice Capital, LLC 31 Mar 2026
T. Rowe Price Investment Management, Inc. 3.7% -65% $24,752,000 -$52,704,175 1,703,510 -68% T. Rowe Price Investment Management, Inc. 30 Apr 2026

As of 31 Mar 2026, 247 institutional investors reported holding 44,822,191 shares of AVANOS MEDICAL, INC. - Common Stock - $0.01 Par Value (AVNS). This represents 96% of the company’s total 46,511,628 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of AVANOS MEDICAL, INC. - Common Stock - $0.01 Par Value (AVNS) together control 78% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 6,843,733 +1.4% 0% $95,880,704
T. Rowe Price Investment Management, Inc. 11% 5,330,776 +19% 0.05% $74,685,000
BROWN ADVISORY INC 4.8% 2,231,198 +15% 0.05% $31,259,092
DIMENSIONAL FUND ADVISORS LP 4.4% 2,052,356 -4.9% 0.01% $28,752,636
ARMISTICE CAPITAL, LLC 4.3% 2,000,000 -38% 0.93% $28,020,000
STATE STREET CORP 4.2% 1,972,523 +0.91% 0% $27,635,047
VANGUARD CAPITAL MANAGEMENT LLC 4.2% 1,971,965 0% 0% $27,627,230
VANGUARD PORTFOLIO MANAGEMENT LLC 2.7% 1,239,295 0% 0% $17,362,523
ACADIAN ASSET MANAGEMENT LLC 2.6% 1,214,930 +27% 0.02% $17,013,000
Thrivent Financial for Lutherans 2.6% 1,187,956 +460% 0.03% $16,644,000
BOONE CAPITAL MANAGEMENT LLC 2.5% 1,184,909 5.1% $16,600,575
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,094,235 +0.9% 0% $15,331,791
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 2.3% 1,058,066 +1.7% 0% $14,823,505
CLARK ESTATES INC/NY 1.8% 845,000 -4.9% 2.8% $11,838,450
MORGAN STANLEY 1.8% 827,662 -24% 0% $11,595,558
AQR CAPITAL MANAGEMENT LLC 1.5% 691,250 -5% 0% $9,608,376
D. E. Shaw & Co., Inc. 1.4% 671,413 -45% 0.01% $9,406,496
AMERIPRISE FINANCIAL INC 1.3% 584,277 +0.29% 0% $8,185,727
DIAMOND HILL CAPITAL MANAGEMENT INC 1.2% 573,940 +13% 0.05% $8,040,899
ROYCE & ASSOCIATES LP 1.1% 513,703 +746% 0.07% $7,196,979
NORTHERN TRUST CORP 1.1% 489,221 +3.4% 0% $6,853,987
GOLDMAN SACHS GROUP INC 1% 480,886 +6.5% 0% $6,737,212
CITADEL ADVISORS LLC 1% 475,196 -0.72% 0% $6,657,496
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. 0.94% 437,085 +62% 0.35% $6,123,561
ExodusPoint Capital Management, LP 0.91% 421,504 -28% 0.06% $5,905,271

Institutional Holders of AVANOS MEDICAL, INC. - Common Stock - $0.01 Par Value (AVNS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 44,822,191 $627,677,917 -$2,871,053 $14.01 247
2025 Q4 45,384,688 $509,776,106 +$5,467,835 $11.23 271
2025 Q3 44,915,629 $519,212,625 -$456,743 $11.56 269
2025 Q2 44,711,937 $547,287,477 +$14,185,298 $12.24 279
2025 Q1 43,396,946 $623,274,490 -$6,741,914 $14.33 275
2024 Q4 43,159,764 $687,053,030 -$348,352 $15.92 253
2024 Q3 42,887,071 $1,030,142,636 +$14,845,110 $24.03 257
2024 Q2 42,331,138 $843,184,184 -$19,844,468 $19.92 254
2024 Q1 43,394,488 $863,829,555 -$12,610,070 $19.91 255
2023 Q4 43,936,227 $986,177,329 +$6,301,621 $22.43 261
2023 Q3 43,653,986 $883,886,301 -$24,810,694 $20.22 251
2023 Q2 44,367,274 $1,134,245,375 +$6,577,133 $25.56 267
2023 Q1 43,807,927 $1,302,667,520 +$18,327,231 $29.74 278
2022 Q4 43,474,984 $1,176,504,936 +$5,615,427 $27.06 274
2022 Q3 43,372,951 $944,662,406 -$2,543,596 $21.78 218
2022 Q2 43,323,037 $1,184,314,252 -$13,685,481 $27.34 227
2022 Q1 43,970,678 $1,472,010,622 +$2,331,652 $33.50 252
2021 Q4 43,852,763 $1,519,830,657 +$2,873,575 $34.67 251
2021 Q3 43,701,330 $1,363,473,910 -$25,618,497 $31.20 229
2021 Q2 44,393,122 $1,614,401,834 +$1,417,948 $36.37 239
2021 Q1 44,092,800 $1,928,597,642 -$45,329,737 $43.74 251
2020 Q4 45,157,960 $2,071,803,289 -$25,305,709 $45.88 240
2020 Q3 45,956,879 $1,526,673,060 -$9,601,150 $33.22 230
2020 Q2 46,293,558 $1,360,488,473 +$21,246,989 $29.39 233
2020 Q1 45,529,610 $1,226,168,208 -$38,883,046 $26.93 219
2019 Q4 45,819,566 $1,543,944,370 +$20,782,780 $33.70 247
2019 Q3 45,225,869 $1,694,273,669 -$5,936,111 $37.46 250
2019 Q2 45,322,055 $1,976,386,420 +$18,591,188 $43.61 277
2019 Q1 45,113,689 $1,925,520,203 +$46,047,746 $42.68 296
2018 Q4 43,999,885 $1,970,607,092 -$23,436,579 $44.79 305
2018 Q3 42,817,781 $2,932,605,954 +$2,861,296,937 $68.50 350
2018 Q2 1,040,879 $59,567,007 +$59,548,000 $57.26 34
2018 Q1 332 $15,299 +$599 $46.08 2
2017 Q4 319 $14,732 $46.18 2
2017 Q3 319 $14,364 -$1,254 $45.03 2
2017 Q2 347 $13,630 $39.28 3
2017 Q1 347 $13,217 -$457 $38.08 3
2016 Q4 359 $13,276 -$2,737 $36.98 3
2016 Q3 432 $14,973 -$1,629 $34.66 2
2016 Q2 479 $15,577 -$6,000 $32.52 2
2016 Q1 611 $19,762 $28.73 3
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .